BR112013026644A2 - método para a modulação da atividade de citocina - Google Patents

método para a modulação da atividade de citocina

Info

Publication number
BR112013026644A2
BR112013026644A2 BR112013026644A BR112013026644A BR112013026644A2 BR 112013026644 A2 BR112013026644 A2 BR 112013026644A2 BR 112013026644 A BR112013026644 A BR 112013026644A BR 112013026644 A BR112013026644 A BR 112013026644A BR 112013026644 A2 BR112013026644 A2 BR 112013026644A2
Authority
BR
Brazil
Prior art keywords
cytokine activity
modulating cytokine
modulating
fatty acid
acid derivative
Prior art date
Application number
BR112013026644A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BR112013026644A2 publication Critical patent/BR112013026644A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "método para a modulação da atividade de citocina". a presente invenção refere se a um método para a modulação da atividade de citocina, imunomodulação ou tratamento de esofagite com-preendendo uma administração de um derivado de ácido graxo a um paciente mamífero. a presente invenção também se refere a uma composição para a modulação da atividade de citocina, imunomodulação ou tratamento de esofagite compreendendo um derivado de ácido graxo.
BR112013026644A 2011-04-19 2012-04-18 método para a modulação da atividade de citocina BR112013026644A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161476992P 2011-04-19 2011-04-19
US201161489516P 2011-05-24 2011-05-24
US201161537305P 2011-09-21 2011-09-21
US201161548458P 2011-10-18 2011-10-18
PCT/JP2012/061004 WO2012144649A1 (en) 2011-04-19 2012-04-18 Method for modulating cytokine activity

Publications (1)

Publication Number Publication Date
BR112013026644A2 true BR112013026644A2 (pt) 2016-12-27

Family

ID=47021806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026644A BR112013026644A2 (pt) 2011-04-19 2012-04-18 método para a modulação da atividade de citocina

Country Status (13)

Country Link
US (1) US20120270945A1 (pt)
EP (1) EP2699244A4 (pt)
JP (1) JP2014511825A (pt)
KR (1) KR20140043075A (pt)
CN (2) CN103781482A (pt)
AU (2) AU2012246999A1 (pt)
BR (1) BR112013026644A2 (pt)
CA (1) CA2831869A1 (pt)
IL (1) IL228700A0 (pt)
MX (1) MX2013012251A (pt)
RU (1) RU2013151166A (pt)
TW (1) TW201247615A (pt)
WO (1) WO2012144649A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008011148A (es) * 2006-02-28 2008-09-08 Sucampo Ag Metodo y composicion para tratar enfermedad pulmonar obstructiva cronica.
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
US20160228403A1 (en) * 2013-10-04 2016-08-11 Tohoku University Agent for preventing or ameliorating renal dysfunction
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
ES2099736T3 (es) * 1990-04-27 1997-06-01 R Tech Ueno Ltd Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias.
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JPH1029942A (ja) * 1996-04-02 1998-02-03 Yoichi Ichikawa 慢性関節リウマチ治療剤
TWI384988B (zh) * 2005-01-27 2013-02-11 Sucampo Ag 處理中樞神經系統失常用之組成物
JP5213448B2 (ja) * 2005-03-04 2013-06-19 スキャンポ・アーゲー 末梢血管疾患の処置のための方法および組成物
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
WO2006109881A1 (en) * 2005-04-12 2006-10-19 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
MX2008011148A (es) * 2006-02-28 2008-09-08 Sucampo Ag Metodo y composicion para tratar enfermedad pulmonar obstructiva cronica.
EP2147672A4 (en) * 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
EP2305304A4 (en) * 2008-04-28 2011-08-10 Nat University Corp Hamamatsu University School Of Medicine IMMUNOSTIMULATOR WITH EP1 AGONIST
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物

Also Published As

Publication number Publication date
CN103781482A (zh) 2014-05-07
CA2831869A1 (en) 2012-10-26
WO2012144649A1 (en) 2012-10-26
AU2017203276A1 (en) 2017-06-08
US20120270945A1 (en) 2012-10-25
IL228700A0 (en) 2013-12-31
JP2014511825A (ja) 2014-05-19
EP2699244A4 (en) 2014-10-22
CN107028952A (zh) 2017-08-11
MX2013012251A (es) 2014-01-20
RU2013151166A (ru) 2015-05-27
TW201247615A (en) 2012-12-01
NZ616027A (en) 2015-09-25
EP2699244A1 (en) 2014-02-26
AU2012246999A1 (en) 2013-10-17
KR20140043075A (ko) 2014-04-08

Similar Documents

Publication Publication Date Title
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112012016879A2 (pt) Derivados de fumarato de acido graxo e seus usos
HRP20130811T1 (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
EP2415749A4 (en) NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
EP2418945A4 (en) Mineral salt-sulfuric acid compositions and methods for their use
BR112012012903A2 (pt) compostos de espiropiperidina
IN2015DN01151A (pt)
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
EA201792072A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA201290603A1 (ru) Способ лечения
BR112013026644A2 (pt) método para a modulação da atividade de citocina
BR112013024968A2 (pt) composição farmacêutica, e, método de tratamento de uma convulsão
IN2013DN02555A (pt)
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
BR112012012000A2 (pt) derivados de quinazolina
BR112014002712A8 (pt) método para tratamento da esquizofrenia
UA112981C2 (uk) Варіант людського gdnf
BR112013000296A2 (pt) agentes terapêuticos 976

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12/02/2019.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI